WEBULL
WebtradeDownload

Is Revolution Medicines (RVMD) Reasonable At 15.9x Book Value?

Simply Wall St · 1d ago

Revolution Medicines has delivered a very large multi year gain, so the key issue now is whether a share price around US$177.65 still lines up with what the balance sheet is actually worth. With a clinical stage oncology pipeline in focus, the question for you is how much of that future promise is already embedded in the stock compared with its book value today.

  • Over roughly three years the share price has risen to almost 7x its earlier level. That puts a lot of pressure on the current valuation to be supported by fundamentals rather than past momentum.
  • Recent earnings news around Revolution Medicines and its RAS targeted cancer programs has lifted expectations for future development progress. This can affect how much weight investors place on book value relative to potential funding needs and future cash flows.
  • There is a second opinion on Revolution Medicines worth weighing. See what analysts think Revolution Medicines's shares could be worth.

The stock's next move may depend on whether the current market value can be squared with Revolution Medicines' book value compared with the industry average.

If you want a wider watchlist while you assess whether Revolution Medicines at around US$177.65 still lines up with its book value, a focused screen of 42 high quality undervalued stocks can be a useful second starting point.

Does Revolution Medicines Look Pricey on Book Value?

A price-to-book lens fits Revolution Medicines because the business is still focused on R&D rather than mature earnings. On this yardstick, the stock trades at a P/B of about 15.9x, compared with a biotech sector average near 1.7x and peer levels around 12.7x. That is a steep premium to the value of its net assets on the balance sheet.

The recent Q3 report that lifted Revolution Medicines shares after hours appears to have reinforced optimism about its oncology pipeline. Yet the current P/B still prices the company well above typical sector valuations. For you as a holder or potential buyer, this means the market is putting a high value on future trial progress and eventual commercialisation rather than the book value today. The key question is whether you believe that gap between price and accounting equity is justified by the pipeline and risk profile at this stage. Explore the numbers behind Revolution Medicines's P/B valuation.

NasdaqGS:RVMD P/B Ratio as at Nov 2026
NasdaqGS:RVMD P/B Ratio as at Nov 2026

The Revolution Medicines Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Revolution Medicines pick up where the valuation puzzle leaves off. They spell out which assumptions about future growth, profitability, and earnings would need to hold for the stock to be worth materially more or less than today's price on the Community page. Rather than relying on a single multiple or model point estimate, each storyline lays out the key moving parts behind its implied value so you can follow how those inputs track against actual results over time.

One of the top community narratives on Revolution Medicines: 31% undervalued

"Three separate RAS(ON) inhibitors with breakthrough therapy designations and a fourth in the clinic, together with a fifth class targeting resistance…"

Discover why this Narrative puts Revolution Medicines at 31% undervalued.

One more question for Revolution Medicines before you move on

The price tag on Revolution Medicines is only part of the story, because the people steering the pipeline and how their rewards are structured can heavily influence what happens next. See who runs Revolution Medicines and how they are paid.